Title : The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.

Pub. Date : 2017 Aug 1

PMID : 28625978






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 IDH1-mutant gliomas are dependent upon the canonical coenzyme NAD+ for survival. NAD isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
2 We therefore hypothesized that a strategy combining NAD+ biosynthesis inhibitors with the alkylating chemotherapeutic agent temozolomide could potentiate NAD+ depletion-mediated cytotoxicity in mutant IDH1 cancer cells. NAD isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
3 We therefore hypothesized that a strategy combining NAD+ biosynthesis inhibitors with the alkylating chemotherapeutic agent temozolomide could potentiate NAD+ depletion-mediated cytotoxicity in mutant IDH1 cancer cells. NAD isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
4 In IDH1-mutant-expressing cells, this consumption reduced further the abnormally lowered basal steady-state levels of NAD+, introducing a window of hypervulnerability to NAD+ biosynthesis inhibitors. NAD isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
5 In IDH1-mutant-expressing cells, this consumption reduced further the abnormally lowered basal steady-state levels of NAD+, introducing a window of hypervulnerability to NAD+ biosynthesis inhibitors. NAD isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens
6 Thus, we find IDH1-mutant cancers have distinct metabolic stress responses to chemotherapy-induced DNA damage and that combination regimens targeting nonredundant NAD+ pathways yield potent anticancer efficacy in vivo Such targeting of convergent metabolic pathways in genetically selected cancers could minimize treatment toxicity and improve durability of response to therapy. NAD isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens